Clinical Trial Results:
A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR* in subjects with moderate to severe chronic malignant tumor-related pain
*PR means Prolonged Release and is the recommended nomenclature for use in EU.
ER means Extended Release and is the recommended nomenclature for use in USA. "PR" is synonymous with "ER" and is interchangeable in the protocol.
Summary
|
|
EudraCT number |
2007-001985-34 |
Trial protocol |
LV FR |
Global completion date |
02 Feb 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Jul 2016
|
First version publication date |
31 Jul 2016
|
Other versions |
|
Summary report(s) |
ClinicalTrials.gov record |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.